Skip to main content
. Author manuscript; available in PMC: 2024 Aug 1.
Published in final edited form as: Alzheimers Dement. 2023 Feb 7;19(8):3272–3282. doi: 10.1002/alz.12963

Table 1.

Demographics and clinical data

Amnestic AD (n=15) Non-amnestic AD (n=19) Controls (n=14) Amnestic vs controls Non-amnestic vs controls Amnestic vs non-amnestic
Age at onset (years) 56.1 ± 9.0 55.7 ± 7.5 N/A N/A N/A ns
Age at EEG (years) 60.6 ± 9.7 60.5 ± 6.7 64.5 ± 5.6 * ns ns
Disease duration (years) 5.1 ± 2.4 5.3 ± 1.9 N/A N/A N/A ns
Female (%) 64.3 57.9 64.3 ns ns ns
Education (years) 15.9 ± 2.5 16.5 ± 2.8 17.4 ± 1.9 ns ns ns
CDR at EEG time (%) 0.86 ± 0.4 0.84 ± 0.4 0 ± 0 ** ** ns
 Normal 0 0 100 N/A N/A N/A
 MCI 43 36.9 0 N/A N/A N/A
 Mild dementia 50 57.9 0 N/A N/A N/A
 Moderate dementia 7 5.2 0 N/A N/A N/A
CDR SoB at EEG time 5.4 ± 2.3 4.6 ± 2.3 0 ± 0 ** ** ns
MMSE at EEG time 21.1 ± 5.7 22. ± 4.5 29.5 ± 0.8 ** ** ns
Anticholinesterase Inhibitors (%) 80 89.5 0 ** ** ns
SSRI Antidepressants (%) 46.7 42.1 7.1 * * ns
Epileptiform activity (%) 20 26.3 0 P=0.07 * ns

Data are shown as mean ± SD

Significance

*

P<0.05

**

P<0.01

ns, non-significant; N/A, not applicable

Abbreviations: CDR, Clinical Dementia rating; CDR-SoB, CDR Sum of Boxes; MMSE, Mini Mental State Examination; SSRI, Selective serotonin reuptake inhibitors